Principia updates anticipated final result from PRN1008 trial
Category: #health  By Pankaj Singh  Date: 2019-12-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Principia updates anticipated final result from PRN1008 trial

Principia Biopharma Inc. recently updated about the anticipated timings for the final result from the ongoing trial of PRN1008 data in patients suffering from pemphigus, along with CRR (complete response rates) from its Phase II Part B trial (open-label).

For the record, Principia Biopharma is a late-stage biopharmaceutical company focused upon developing transformative oral therapies for patients with major unmet medical needs for immune-mediated diseases.

Dolca Thomas, MD and Chief Medical Officer of Principia Biopharma was reportedly quoted saying that the company is pleased to witness the interest in the Phase 3 PEGASUS trial and through the hard work of its study coordinators, investigators and clinical team, the enrollment timelines have speeded up. The final data from the trial which was supposed to be completed in the first half of 2022 will now be updated by the second half of 2021.

Thomas added saying that the company is exhilarated to witness a 40% CRR in the Phase 2 Part B trial (six patients) in spite of most patients being treated initially at a sub-therapeutic 400 mg daily dose.

Among the 15 patients which were dosed in Part B of the Phase 2 clinical trial, 60% (nine) of them achieved the primary endpoint of CDA (control of disease activity) by week 4 on low dose corticosteroids, which was equal to or less than 0.5 mg/kg per day.

12 out of 15 patients, equivalent to 80%, achieved control of disease activity by 12th week. 9 of the 15 patients (60%) have achieved a PDAI score of 1 or 0 (PDAI scoring system indicates disease severity). Safety and efficacy of PRN1008 turned out to be consistent with Phase 2 Part A trial and was also well-tolerated in Part B with no treatment-related serious AE (adverse event) reported. At an upcoming medical conference, final data from the Phase 2 Part B trial will be submitted for presentation.
 

Source Credit: https://ir.principiabio.com/news-releases/news-release-details/principia-updates-prn1008-pemphigus-clinical-program

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Construction sector accountable for 37% of carbon emissions, UN report
Construction sector accountable for 37% of carbon emissions, UN report
By Pankaj Singh

A new research by the United Nations shows a grim picture of the climate situation. The report states that 37% of energy-related carbon dioxide emissions are coming from the construction sector. According to the UN, lockdowns imposed worldwide durin...

Alaska Airlines launches new investment arm to develop mobility tech
Alaska Airlines launches new investment arm to develop mobility tech
By Pankaj Singh

Alaska Airlines, a major American airline, has introduced a new venture capital subdivision called Alaska Star Ventures. The launch comes at a time when the aviation sector is looking to develop technologies that help decarbonize air travel. Alaska ...

Bettervest invests in Oakridge Rooftops to support solar projects
Bettervest invests in Oakridge Rooftops to support solar projects
By Pankaj Singh

Oakridge Rooftops Pvt. Ltd., a solar energy company based in India, has reportedly secured funding from Germany-based crowdfunding platform, Bettervest Gmbh. The solar firm has raised the funding for urban solar projects in New Delhi. Oakridge CEO, ...